11月25日，阿拉丁盘中上涨2.05%，截至13:48，报12.95元/股，成交3396.51万元，换手率0.79%，总市 值43.07亿元。 资金流向方面，主力资金净流入196.49万元，大单买入848.84万元，占比24.99%，卖出652.35万元，占 比19.21%。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比增长17.59%；归母净利润5776.03万元，同比减少 20.41%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 责任编辑：小浪快报 阿拉丁今年以来股价涨14.27%，近5个交易日跌3.14%，近20日涨5.46%，近60日跌17.83%。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日 ...

Core Points - Aladdin's stock price decreased by 2.04% on November 17, trading at 13.42 CNY per share with a market capitalization of 4.464 billion CNY [1] - The company has seen an 18.42% increase in stock price year-to-date, with a 1.51% rise over the last five trading days and an 11.37% increase over the last 20 days, but a 13.36% decline over the last 60 days [2] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [2] - As of September 30, 2025, Aladdin reported a revenue of 444 million CNY, a year-on-year increase of 17.59%, while net profit attributable to shareholders decreased by 20.41% to 57.76 million CNY [2] Financials - The company has distributed a total of 241 million CNY in dividends since its A-share listing, with 150 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] Shareholder Information - The top ten circulating shareholders have seen changes, with several funds exiting the list as of September 30, 2025 [3]

Core Points - Aladdin's stock price increased by 2.07% on November 10, reaching 13.31 CNY per share, with a total market capitalization of 4.427 billion CNY [1] - The company reported a year-to-date stock price increase of 17.44%, with a recent 5-day increase of 3.26% and a 60-day decrease of 11.27% [1] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [1] Financial Performance - For the period from January to September 2025, Aladdin achieved operating revenue of 444 million CNY, representing a year-on-year growth of 17.59% [2] - The net profit attributable to the parent company was 57.76 million CNY, showing a year-on-year decrease of 20.41% [2] Shareholder Information - As of September 30, 2025, the number of Aladdin's shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million CNY in dividends, with 150 million CNY distributed in the last three years [3] - Notably, some institutional investors exited the top ten circulating shareholders list as of September 30, 2025 [3]

Core Insights - Zunyi Medical University has announced four procurement intentions for laboratory equipment, with a total budget of 105 million yuan [1][2]. Procurement Overview - The procurement includes projects for research platform construction, teaching platform construction, experimental consumables, and reagents [2]. - The expected procurement period is from June to October 2025 [2]. Detailed Procurement List - Research Platform Construction Project: Budget of 49.99 million yuan, aimed at enhancing research capabilities [4]. - Teaching Platform Construction Project: Budget of 49.97 million yuan, focused on improving teaching facilities [4]. - Pharmaceutical Experimental Teaching Demonstration Center: Budget of 1.52 million yuan, intended to enhance experimental capabilities [4]. - Experimental Consumables and Reagents: Budget of 4 million yuan, aimed at meeting teaching and research needs [5]. Institutional Background - Zunyi Medical University is a key institution for medical education in China, with a strong emphasis on interdisciplinary research in biology, chemistry, environment, and materials [5]. - The university has established several high-level research platforms, including key laboratories in pharmacology and oncology, contributing significantly to regional economic and social development [6].

Core Insights - Aladdin's revenue for the first three quarters of 2025 reached 444 million yuan, representing a year-on-year increase of 17.59% [1] - The company's net profit attributable to shareholders was 57.76 million yuan, a year-on-year decrease of 20.41% [1] - The basic earnings per share stood at 0.17 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 63.02%, a slight decrease of 0.06 percentage points year-on-year [2] - The net profit margin was 17.38%, down 4.96 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin improved to 66.27%, an increase of 4.44 percentage points year-on-year and 6.02 percentage points quarter-on-quarter [2] - The net profit margin for Q3 2025 was 22.81%, up 0.36 percentage points year-on-year and increased by 16.56 percentage points from the previous quarter [2] Expense Analysis - Total operating expenses for the period were 183 million yuan, an increase of 52.47 million yuan year-on-year [2] - The expense ratio was 41.32%, up 6.63 percentage points from the same period last year [2] - Sales expenses increased by 38.45%, management expenses rose by 38.37%, R&D expenses grew by 10.84%, and financial expenses surged by 761.11% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 11,600, a decrease of 894 from the end of the previous half-year, representing a decline of 7.17% [2] - The average market value per shareholder increased from 339,200 yuan at the end of the previous half-year to 374,400 yuan, a growth of 10.35% [2] Company Overview - Shanghai Aladdin Biochemical Technology Co., Ltd. was established on March 16, 2009, and went public on October 26, 2020 [3] - The company's main business involves the research, development, production, and sales of reagents, with research reagents accounting for 96.96% of revenue [3] - Aladdin operates in the basic chemical industry, specifically in the chemical products sector, and is associated with concepts such as synthetic biology, e-commerce, scientific instruments, and specialized innovation [3]

Group 1 - Aladdin Biochemical Technology Co., Ltd. experienced a stock price increase of 5.18%, reaching 12.99 CNY per share, with a trading volume of 100 million CNY and a turnover rate of 2.37%, resulting in a total market capitalization of 4.321 billion CNY [1] - The company, established on March 16, 2009, and listed on October 26, 2020, focuses on the research, production, and sales of reagents, with its main revenue sources being research reagents (96.96%), laboratory consumables (2.15%), and other supplementary products (0.89%) [1] Group 2 - Morgan Stanley's fund, specifically the Morgan Stanley Yu Yue An He Mixed A Fund (009893), has a significant position in Aladdin, having increased its holdings by 59,700 shares in the second quarter, totaling 275,900 shares, which represents 5.24% of the fund's net value, making it the sixth-largest holding [2] - The Morgan Stanley Yu Yue An He Mixed A Fund was established on September 24, 2020, with a current size of 28.9066 million CNY, achieving a year-to-date return of 22.61% and a one-year return of 35.66%, ranking 4240 out of 8171 and 4277 out of 8004 in its category, respectively [2]

Core Viewpoint - Aladdin's stock price has shown fluctuations in recent trading periods, with a current market capitalization of 4.194 billion yuan and a notable increase in share price of 11.27% year-to-date [1][2]. Financial Performance - For the first half of 2025, Aladdin achieved a revenue of 275 million yuan, reflecting a year-on-year growth of 15.45%, while the net profit attributable to shareholders decreased by 39.79% to 28.4635 million yuan [2]. - Cumulatively, Aladdin has distributed 241 million yuan in dividends since its A-share listing, with 150 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 26, Aladdin's stock rose by 2.11% to 12.61 yuan per share, with a trading volume of 13.1574 million yuan and a turnover rate of 0.32% [1]. - The net inflow of main funds was 1.6862 million yuan, with large orders accounting for 19.87% of purchases and 7.05% of sales [1]. Shareholder Structure - As of June 30, 2025, Aladdin had 12,500 shareholders, an increase of 22.88% from the previous period, with an average of 26,670 circulating shares per shareholder, a decrease of 2.42% [2]. - Among the top ten circulating shareholders, several funds have adjusted their holdings, with notable changes in the shares held by various funds [3].

Company Overview - Aladdin Biochemical Technology Co., Ltd. is located at 36 Nanta, Xinjinqiao Road, Pudong New District, Shanghai, established on March 16, 2009, and listed on October 26, 2020. The company specializes in the research, production, and sales of reagents, with main business revenue composition: 96.96% from research reagents, 2.15% from laboratory consumables, and 0.89% from other sources [1]. Stock Performance - As of September 3, Aladdin's stock price decreased by 0.92%, trading at 12.91 CNY per share, with a total transaction volume of 86.79 million CNY and a turnover rate of 2.00%. The total market capitalization stands at 4.294 billion CNY. The stock has experienced a continuous decline for 8 days, with a cumulative drop of 18.6% during this period [1]. Fund Holdings - Morgan Stanley's fund has a significant position in Aladdin, with the "Morgan Stanley Youyue Anhe Mixed A" fund (009893) increasing its holdings by 59,700 shares in the second quarter, totaling 275,900 shares, which accounts for 5.24% of the fund's net value, ranking it as the sixth-largest holding. The estimated floating loss today is approximately 33,100 CNY, with a total floating loss of 813,800 CNY during the 8-day decline [2]. Fund Performance - The "Morgan Stanley Youyue Anhe Mixed A" fund was established on September 24, 2020, with a current size of 28.9066 million CNY. Year-to-date returns are 20.64%, ranking 3666 out of 8180 in its category, while the one-year return is 31.74%, ranking 4447 out of 7967. Since inception, the fund has incurred a loss of 28.99% [2]. Fund Manager Information - The fund manager of "Morgan Stanley Youyue Anhe Mixed A" is Zhao Weijie, who has been in the position for 4 years and 185 days. The total asset size under management is 305 million CNY, with the best fund return during his tenure being 23.35% and the worst being -31% [2].

Group 1 - Titan Technology's stock price closed at 29.41 yuan on August 26, 2025, down 0.75 yuan or 2.49% from the previous trading day [1] - The stock opened at 30.20 yuan, reached a high of 30.70 yuan, and a low of 29.16 yuan, with a trading volume of 53,000 hands and a transaction amount of 157 million yuan [1] - The company experienced a net inflow of 250,000 yuan from a transaction of 100,000 shares at a price of 25.00 yuan, which was a discount of 14.99% compared to the closing price [1] Group 2 - Titan Technology operates in the professional services industry, providing research reagents, laboratory consumables, and equipment, primarily serving research institutions, universities, and corporate R&D departments [1] - The main capital inflow for the company was 16.34 million yuan, with a cumulative net inflow of 10.97 million yuan over the past five days [1]

Investment Rating - The industry investment rating is "Outperform the Market - A" [3][27] Core Insights - The trend of self-control in the research service and upstream sectors is deepening, presenting significant development opportunities for domestic manufacturers due to U.S. export controls and reciprocal tariffs [1][2] - The import dependence and trade deficit in scientific instruments are high, with a low domestic production rate. In 2023, China's scientific instrument imports were approximately 17 billion USD, while exports were about 4.3 billion USD, indicating a substantial trade deficit [7][14] - The recent U.S. export controls and tariff increases have heightened the importance of self-sufficiency in the domestic scientific instrument industry, with significant opportunities expected for domestic manufacturers in various segments [22][18] Summary by Sections 1. Scientific Instruments: Core Track Under Self-Control Trend - Current Situation: High import dependence, large trade deficit, and low domestic production rates. The market for high-end scientific instruments is dominated by imported brands [7][14] - Marginal Changes: U.S. export controls and reciprocal tariffs have increased the urgency for self-sufficiency in the domestic scientific instrument supply chain [18][22] - Outlook: The procurement difficulty and costs for imported scientific instruments are expected to rise, reshaping the market landscape and providing growth opportunities for domestic manufacturers such as Haier Biomedical and East China Pharmaceutical [22][9] 2. Research Reagents and Laboratory Consumables: Acceleration of Domestic Substitution - The impact of U.S. tariffs on imports may benefit domestic products, particularly in the research reagent and laboratory consumables sectors, where the domestic production rate is low [2][23] - The market for laboratory consumables in China was approximately 57.55 billion CNY in 2023, with a compound annual growth rate (CAGR) of about 20% from 2019 to 2023 [25] - Potential beneficiaries of the domestic substitution trend include companies like Nanwei Technology and Aolimai, which have a significant domestic revenue structure [24][9]